cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aclaris Therapeutics Inc
40 own
38 watching
Current Price
$1.57
$0.02
(1.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
87.09M
52-Week High
52-Week High
5.17000
52-Week Low
52-Week Low
0.95200002
Average Volume
Average Volume
0.75M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization87.09M
icon52-Week High5.17000
icon52-Week Low0.95200002
iconAverage Volume0.75M
iconDividend Yield--
iconP/E Ratio--
What does the Aclaris Therapeutics Inc do?
Developing a proprietary hydrogen peroxide treatment for common skin lesions.
Read More
How much money does Aclaris Therapeutics Inc make?
News & Events about Aclaris Therapeutics Inc.
Stock Options Channel
1 year ago
Investors eyeing a purchase of Aclaris Therapeutics Inc (ACRS) shares, but tentative about paying the going market price of 9.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February ...
Ticker Report
2years ago
Aclaris Therapeutics, Inc. (NASDAQ:ACRS Get Rating) Stock analysts at Jefferies Financial Group boosted their FY2025 earnings per share estimates for Aclaris Therapeutics in a note issued to investors on Monday, March 6th. Jefferies Financial Group analyst R. Song now expects that ...
Zolmax
2years ago
Aclaris Therapeutics (NASDAQ:ACRS Get Rating) had its target price decreased by The Goldman Sachs Group from $25.00 to $21.00 in a report released on Tuesday , Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology companys stock. Several other research analysts ...
Benzinga
2years ago
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. read more...
Globe Newswire
2years ago
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. 2023 is setting up to be an incredibly ...
Frequently Asked Questions
Frequently Asked Questions
What is Aclaris Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aclaris Therapeutics Inc shares?
plus_minus_icon
How can I buy Aclaris Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aclaris Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aclaris Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aclaris Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aclaris Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aclaris Therapeutics Inc?
plus_minus_icon
What percentage is Aclaris Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aclaris Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.57
$0.02
(1.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00